glp-1 pharma Market Expected to More Than Double to $190B by 2035 Ease your GLP As GLP-1 Use Expands, Long-Term

Efficacy of Liraglutide in overweight and obese women with PCOS: A randomized, double-blind, placebo-controlled study

This is dangerous because people with eating disorders are already at risk for nutritional deficiencies and disordered relationships with food

The recurring theme is the same: the weekly-to-daily shift is where routines break

Practical considerations: Document BMI, comorbidities, and informed consent like any obesity specialist would Consider interactions between weight-loss meds and psychiatric medications (e.g., phentermines stimulant effects in patients with anxiety or bipolar disorder) Be prepared to provide or coordinate nutrition counseling and lifestyle modification (many states like New Jersey explicitly require this) Schedule appropriate follow-ups (quarterly minimum in Florida, monthly recommended early in treatment nationally) Risk mitigation: Some psychiatrists pursue additional certification through the American Board of Obesity Medicine (ABOM) to bolster credibility and demonstrate competence

These properties made GLP-1 receptor agonists a breakthrough class of medications for type 2 diabetes and obesity